Back to Search
Start Over
High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia.
- Source :
-
Cancer Cell International . 5/7/2019, Vol. 19 Issue 1, pN.PAG-N.PAG. 1p. - Publication Year :
- 2019
-
Abstract
- Background: Acute myeloid leukemia (AML) pertains to a hematologic malignancy with heterogeneous therapeutic responses. Improvements in risk stratification in AML patients are warranted. MicroRNAs have been associated with the pathogenesis of AML. Methods: To examine the prognostic value of miR-25, 162 cases with de novo AML were classified into two groups according to different treatment regimens. Results: In the chemotherapy group, cases with upregulated miR-25 expression showed relatively longer overall survival (OS; P = 0.0086) and event-free survival (EFS; P = 0.019). Multivariable analyses revealed that miR-25 upregulation is an independent predictor for extended OS (HR = 0.556, P = 0.015) and EFS (HR = 0.598, P = 0.03). In addition, allogeneic hematopoietic stem cell transplantation (allo-HSCT) circumvented the poor prognosis that was related to miR-25 downregulation with chemotherapy. The expression level pattern of miR-25 coincided with AML differentiation and proliferation, which included HOXA and HOXB cluster members, as well as the HOX cofactor MEIS1. The MYH9 gene was identified as a direct target of miR-25. Conclusions: The miR-25 levels are correlated with prognosis in AML independently of other powerful molecular markers. The expression of miR-25 may contribute to the selection of the optimal treatment regimen between chemotherapy and allo-HCST for AML patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14752867
- Volume :
- 19
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Cancer Cell International
- Publication Type :
- Academic Journal
- Accession number :
- 136274260
- Full Text :
- https://doi.org/10.1186/s12935-019-0843-9